Dual-action weight loss without needles
Pricing varies by protocol
The dual GIP/GLP-1 receptor agonist in a sublingual formulation that dissolves under the tongue. Absorption of this compounded sublingual formulation has not been studied — the injectable is the form with clinical evidence behind it, and it's what we recommend. If needles are a genuine barrier, your provider will talk through the tradeoff. Dose titration is managed and monitored throughout.
Licensed Providers · Lab-Guided · Ongoing Support
This treatment may be right for you if you identify with any of the following:
Explore alternative treatments your provider may recommend
Take the first step with a clinician-guided evaluation. Personalized protocols, compounded medications, ongoing support.
Take the Weight Loss QuizTirzepatide Sublingual at RenewRx starts at $450/month. That includes your provider consultation, protocol design, and lab monitoring every 90 days — there is no separate membership fee stacked on top. Final pricing depends on the dose and protocol your clinician prescribes after reviewing your bloodwork.
RenewRx dispenses compounded tirzepatide from a licensed 503A pharmacy. Compounded medications are prepared for an individual patient and are not FDA-approved. The FDA-approved branded version is Zepbound and Mounjaro (injectable). We'd rather tell you that plainly than let you assume otherwise — your provider will walk you through what it means before you start.
A tablet that dissolves under your tongue, absorbed through the tissue in your mouth rather than the digestive tract. No needles.
We recommend the injectable, and we'll tell you why. The once-weekly injection is the form with clinical evidence behind it — the trial data, the dosing, the outcomes. Compounded sublingual tirzepatide has not been studied for absorption, so we can't give you a reliable timeline for this route. If needles are a genuine barrier for you, your provider will talk through the tradeoff honestly — but you should know you're choosing convenience over certainty.
Gastrointestinal effects — nausea, constipation, diarrhea — are the most common, typically easing as your body adjusts. Some patients report mouth or tongue irritation from the dissolving tablet. Important: GLP-1 medications carry a boxed warning for thyroid C-cell tumors. They are not appropriate for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Tell your provider if either applies to you.
Yes. Every RenewRx protocol begins with a lab panel reviewed by a licensed provider before anything is prescribed. We won't write a prescription off a questionnaire alone. Labs are rechecked every 90 days so your dose is adjusted to how you're actually responding — not to how you're expected to respond.
One honest reason: you won't do the injection. That's a legitimate reason, and a treatment you'll actually take beats one you avoid. But understand the tradeoff — Tirzepatide injections have clinical evidence behind them and compounded sublingual tirzepatide has never been studied for absorption. You're choosing convenience over certainty. Your provider will recommend the injection first, and will tell you why.
Most of the benefit fades once you stop, because these therapies manage a condition rather than cure it. That said, the goal isn't to keep you on medication forever — your provider will talk with you about duration, tapering, and what an exit looks like. If a clinic never raises that conversation, ask why.
No contract, and no lock-in. Our protocols are structured as three-month programs because that's the window where the physiology actually shows up — hormone and peptide therapy needs time, plus at least one lab recheck, before anyone can honestly say whether it's working. You're committing to giving the protocol a fair trial, not to a contractual obligation.
Answers reviewed and approved by RenewRx clinical staff. This information is educational and is not medical advice or a substitute for evaluation by a licensed provider. Pricing reflects current protocols and may change.
